Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 86

1.

[Epidemiological and biologic profile of breast cancer in Fez-Boulemane, Morocco].

Abbass F, Bennis S, Znati K, Akasbi Y, Amrani JK, El Mesbahi O, Amarti A.

East Mediterr Health J. 2011 Dec;17(12):930-6. French.

PMID:
22355946
[PubMed - indexed for MEDLINE]
2.

p53 as a marker of prognosis in African-American women with breast cancer.

Dookeran KA, Dignam JJ, Ferrer K, Sekosan M, McCaskill-Stevens W, Gehlert S.

Ann Surg Oncol. 2010 May;17(5):1398-405. doi: 10.1245/s10434-009-0889-3. Epub 2010 Jan 5.

PMID:
20049641
[PubMed - indexed for MEDLINE]
3.

Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.

Lee JA, Kim KI, Bae JW, Jung YH, An H, Lee ES; Korean Breast Cancer Society.

Breast Cancer Res Treat. 2010 Aug;123(1):177-87. doi: 10.1007/s10549-010-0998-5. Epub 2010 Jun 24.

PMID:
20574671
[PubMed - indexed for MEDLINE]
4.

Is triple negative a prognostic factor in breast cancer?

Nishimura R, Arima N.

Breast Cancer. 2008;15(4):303-8. doi: 10.1007/s12282-008-0042-3. Epub 2008 Mar 29.

PMID:
18369692
[PubMed - indexed for MEDLINE]
5.

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.

PMID:
16959170
[PubMed - indexed for MEDLINE]
Free Article
6.

Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.

Linderholm B, Bergqvist J, Hellborg H, Johansson U, Linderholm M, von Schoultz E, Elmberger G, Skoog L, Bergh J.

Med Oncol. 2009 Dec;26(4):480-90. doi: 10.1007/s12032-008-9157-9. Epub 2009 Jan 7.

PMID:
19130322
[PubMed - indexed for MEDLINE]
7.

Pregnancy and breast cancer: a population-based study.

Reed W, Hannisdal E, Skovlund E, Thoresen S, Lilleng P, Nesland JM.

Virchows Arch. 2003 Jul;443(1):44-50. Epub 2003 May 20.

PMID:
12756565
[PubMed - indexed for MEDLINE]
8.

Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival.

Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA.

J Surg Res. 2007 Nov;143(1):109-18.

PMID:
17950079
[PubMed - indexed for MEDLINE]
9.

Factors associated with HER2 overexpression in breast cancer: Experience in an Asian developing country.

Tan GH, Choo WY, Taib NA, Yip CH.

Asian Pac J Cancer Prev. 2009;10(5):837-40.

PMID:
20104975
[PubMed - indexed for MEDLINE]
Free Article
10.

Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.

Sanpaolo P, Barbieri V, Genovesi D.

Eur J Surg Oncol. 2011 Oct;37(10):876-82. doi: 10.1016/j.ejso.2011.07.001. Epub 2011 Aug 6.

PMID:
21824742
[PubMed - indexed for MEDLINE]
11.

Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients.

Knoop AS, Bentzen SM, Nielsen MM, Rasmussen BB, Rose C.

J Clin Oncol. 2001 Jul 15;19(14):3376-84.

PMID:
11454885
[PubMed - indexed for MEDLINE]
Free Article
12.

Twelve cases of metaplastic carcinoma of the breast: experience of the university hospital of Fez Morocco.

Znati K, Chahbouni S, Hammas N, Bennis S, Abbas F, Harmouch T, Chbani L, Elfatemi H, Amarti A.

Arch Gynecol Obstet. 2011 Apr;283(4):845-9. doi: 10.1007/s00404-010-1474-5. Epub 2010 May 8.

PMID:
20454905
[PubMed - indexed for MEDLINE]
13.

Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer.

Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Van Limbergen E, Berteloot P, Amant F, Vergote I, Christiaens MR.

Ann Oncol. 2005 Nov;16(11):1755-61. Epub 2005 Aug 5.

PMID:
16085689
[PubMed - indexed for MEDLINE]
Free Article
14.

Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.

Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Dellapasqua S, Iorfida M, Cardillo A, Veronesi P, Luini A, Intra M, Gentilini O, Scarano E, Goldhirsch A, Colleoni M.

Breast Cancer Res Treat. 2011 Jun;127(3):713-20. doi: 10.1007/s10549-011-1465-7. Epub 2011 Mar 31.

PMID:
21452022
[PubMed - indexed for MEDLINE]
15.

LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.

Saha B, Zhang N, Naritoku WY, Tsao-Wei DD, Groshen SL, Carlsson G, Larsson L, Gustavsson B, Chaiwun B, Taylor CR, Imam SA.

Anticancer Res. 2004 Jul-Aug;24(4):2391-400.

PMID:
15330189
[PubMed - indexed for MEDLINE]
Free Article
16.

Tumor marker phenotype concordance in second primary breast cancer, California, 1999-2004.

Brown M, Bauer K, Pare M.

Breast Cancer Res Treat. 2010 Feb;120(1):217-27. doi: 10.1007/s10549-009-0469-z. Epub 2009 Jul 21.

PMID:
19629680
[PubMed - indexed for MEDLINE]
17.

Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.

Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S.

J Clin Pathol. 2008 Mar;61(3):327-32. Epub 2007 Nov 23.

PMID:
18037662
[PubMed - indexed for MEDLINE]
18.

Prognosis of a series of 763 consecutive node-negative invasive breast cancer patients without adjuvant therapy: analysis of clinicopathological prognostic factor.

Saimura M, Fukutomi T, Tsuda H, Sato H, Miyamoto K, Akashi-Tanaka S, Nanasawa T.

J Surg Oncol. 1999 Jun;71(2):101-5.

PMID:
10389866
[PubMed - indexed for MEDLINE]
19.

[Prognostic value of estradiol and progesterone receptors in stage I and II breast cancer with an adjuvant treatment].

Bolla M, Bonnabel P, Chedin M, Villemain D, Zins M, Mousseau M, Chambaz E.

Bull Cancer. 1987;74(6):623-30. French.

PMID:
3435786
[PubMed - indexed for MEDLINE]
20.

Prognostic factors affecting disease-free survival rate following surgical resection of primary breast cancer.

Horita K, Yamaguchi A, Hirose K, Ishida M, Noriki S, Imamura Y, Fukuda M.

Eur J Histochem. 2001;45(1):73-84.

PMID:
11411868
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk